The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment
Open accessAbstract
A long-acting factor VIII (FVIII) as a replacement therapy for hemophilia A would significantly improve treatment options for patients with hemophilia A. To develop a FVIII with an extended circulating half-life, but without a reduction in activity, we have engineered 23 FVIII variants with introduced surface-exposed cysteines to which a polyethylene glycol (PEG) polymer was specifically conjugated. Screening of variant expression level, PEGylation yield, and functional assay identified several conjugates retaining full in vitro coagulation activity and von Willebrand factor (VWF) binding.PEGylated FVIII variants exhibited improved pharmacokinetics in hemophilic mice and rabbits. In addition, pharmacokinetic studies in VWF knockout mice indicated that larger molecular weight PEG may substitute for VWF in protecting PEGylated FVIII from clearance in vivo. In bleeding models of hemophilic mice, PEGylated FVIII not only exhibited prolonged efficacy that is consistent with the improved pharmacokinetics but also showed efficacy in stopping acute bleeds comparable with that of unmodified rFVIII. In summary site-specifically PEGylated FVIII has the potential to be a long-acting prophylactic treatment while being fully efficacious for on-demand treatment for patients with hemophilia A.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lind, P., Larsson, K., Spira, J., Sydow‐Báckman, M., Almstedt, A., Gray, E., & Sandberg, H. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20776.x · Cited by 120
Almstedt, A., Brandt, J., Gray, E., Holmquist, L., Oswaldsson, U., Sebring, S., Mikaelsson, M., & Sandberg, H. (2001) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1612910 · Cited by 85
Cited by
The past and future of haemophilia: diagnosis, treatments, and its complications
Peyvandi, F., Garagiola, I., & Young, G. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01123-x · Cited by 505
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Mahlangu, J., Powell, J. S., Ragni, M. V., Chowdary, P., Josephson, N. C., Pabinger, I., Hanabusa, H., Gupta, N., Kulkarni, R., Fogarty, P., et al. (2014) · Blood · doi:10.1182/blood-2013-10-529974 · Cited by 454
Self-citationBerntorp, E., & Shapiro, A. D. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61139-2 · Cited by 335
Picanco-Castro, V., Biaggio, R., Cova, D., & Swiech, K. (2013) · Protein & Peptide Letters · doi:10.2174/092986652012131112130322 · Cited by 34
Industrial production of clotting factors: challenges of expression, and choice of host cells
Kumar, S. R. (2015) · Biotechnology Journal · doi:10.1002/biot.201400666 · Cited by 31
Metadata
- Authors
- Mei, B., Pan, C., Jiang, H., Tjandra, H., Strauss, J., Chen, Y., Liu, T., Zhang, X., Severs, J., Newgren, J., Chen, J., Gu, J.-M., Subramanyam, B., Fournel, M. A., Pierce, G. F., & Murphy, J. E.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-07-15
- Volume
- 116
- Issue
- 2
- Pages
- 270-279
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2090145179
- Cited by
- 229
- References
- 2
- FWCI
- 12.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. https://app.cochat.ai/papers/10.1182/blood-2009-11-254755
- The paper
- Mei, B., Pan, C., Jiang, H., Tjandra, H., Strauss, J., Chen, Y., Liu, T., Zhang, X., Severs, J., Newgren, J., Chen, J., Gu, J.-M., Subramanyam, B., Fournel, M. A., Pierce, G. F., & Murphy, J. E. (2010). Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood. https://doi.org/10.1182/blood-2009-11-254755
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.